GlaxoSmithKline plc (LON:GSK) had its price objective hoisted by investment analysts at Jefferies Group from GBX 1,900 ($23.51) to GBX 1,950 ($24.13) in a report issued on Thursday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target points to a potential upside of 14.71% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Monday, June 20th. Deutsche Bank AG reissued a “hold” rating and set a GBX 1,870 ($23.14) target price on shares of GlaxoSmithKline plc in a research note on Wednesday. HSBC reissued a “buy” rating and set a GBX 1,970 ($24.38) target price on shares of GlaxoSmithKline plc in a research note on Monday, September 12th. Berenberg Bank set a GBX 1,885 ($23.33) target price on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a research note on Tuesday, August 9th. Finally, Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 21st. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 1,687.13 ($20.88).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1700.00 on Thursday. The firm has a 50-day moving average of GBX 1,648.78 and a 200 day moving average of GBX 1,560.13. The company’s market cap is GBX 82.64 billion. GlaxoSmithKline plc has a 52 week low of GBX 1,277.25 and a 52 week high of GBX 1,745.56.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The business also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Thursday, August 11th will be given a GBX 19 ($0.24) dividend. This represents a dividend yield of 1.12%. The ex-dividend date of this dividend is Thursday, August 11th.

In related news, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.95), for a total value of £169,300 ($209,529.70). Also, insider Slaoui,Moncef bought 28 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The stock was bought at an average cost of GBX 2,208 ($27.33) per share, for a total transaction of £618.24 ($765.15).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with's FREE daily email newsletter.